Early Onset Familial AD
Important Notice: Alzheimer Research Forum does not provide medical advice nor promote any product or service. The contents are for informational purposes only and are not intended to substitue for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on this web site. The views of individuals quoted on this site are not necessarily those of the Alzheimer Research Forum.
This section presents essays on human studies of early onset familial AD (eFAD). Families with this condition have been excluded from drug studies, even though the genes causing disease in their families have done much to advance AD research in the past 15 years. Why is that? The essays in this section aim to illuminate some of the complex issues of drug research in AD that make it challenging to design clinical trials for eFAD. In addition, we aim to articulate how eFAD families hold out the tantalizing prospect of moving drug research toward prevention of this disease, and what kind of observational clinical research could set the stage for eventual prevention studies.
- Clinical Trials: Why Are eFad Patients Excluded? Will That Change?
- Drug Trials in Early Onset AD
- Interview: A Spouse's Perspective on Clinical Trials for eFAD
- Prevention - Do eFAD Families Hold the Key?
- Devil in the Details - The Challenges of Prevention Trials
- Sidebar: Prevention With Statins: Can the Brain Learn From the Heart?
- Where to Turn for Research: Human Studies of eFAD
NEXT: Clinical Trials: Why Are eFAD Patients Excluded? Will That Change?